Alza Concerta Marketing May Expand ADHD Market, Aid Adderall - Shire CEO
Executive Summary
Shire sees preliminary evidence that Alza's marketing of Concerta could expand the ADHD market for Adderall, CEO Rolf Stahel said during an Oct. 31 conference call.
You may also be interested in...
Alza Concerta Climbs To 15% Of ADHD Market With 170,000 Patients
Alza Concerta holds 15% of the attention deficit hyperactive disorder market, Senior VP-Sales & Marketing Dan Swisher told the company's annual analyst meeting in New York City Feb. 27.
Alza Concerta Climbs To 15% Of ADHD Market With 170,000 Patients
Alza Concerta holds 15% of the attention deficit hyperactive disorder market, Senior VP-Sales & Marketing Dan Swisher told the company's annual analyst meeting in New York City Feb. 27.
Shire Adderall DTC Superiority Claims Require Stronger Clinical Data - FDA
Data presented in Shire's Adderall (amphetamine) promotional materials demonstrate comparability between Adderall and Novartis' Ritalin (methylphenidate) at lower doses, rather than superiority, as the promotional materials claim, an FDA ad division letter to Shire maintains.